Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care
- PMID: 32795720
- PMCID: PMC7415167
- DOI: 10.1016/j.thromres.2020.08.010
Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care
Conflict of interest statement
WT – speakers fees from Pfizer, Bayer, Takeda and advisory boards for Daiichi-Sankyo, Sanofi and Ablynx. SM – support to attend educational meetings from Sysmex, Werfen and Stago. MB – speakers fee from Stago, and advisory boards for Novartis, Cosmopharma, Werfen, Agios and a grant from Mitsubishi. DW & SC-M – none to declare.
Comment on
-
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.J Thromb Haemost. 2020 Jul;18(7):1743-1746. doi: 10.1111/jth.14869. Epub 2020 May 27. J Thromb Haemost. 2020. PMID: 32320517 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical